Shin Nippon Biomedical Laboratories, Ltd.

Symbol: 2395.T

JPX

1392

JPY

Markedspris i dag

  • 10.3343

    P/E-forhold

  • -0.0844

    PEG Ratio

  • 57.95B

    MRK Cap

  • 0.04%

    DIV Udbytte

Shin Nippon Biomedical Laboratories, Ltd. (2395-T) Årsregnskaber

På diagrammet kan du se standardtallene i dynamik for Shin Nippon Biomedical Laboratories, Ltd. (2395.T). Virksomhedens omsætning viser gennemsnittet af NaN M, som er NaN % gowth. Den gennemsnitlige bruttofortjeneste for hele perioden er NaN M, som er NaN %. Den gennemsnitlige bruttofortjeneste er NaN %. Væksten i nettoindkomst for virksomheden sidste år er NaN %, hvilket svarer til NaN % % i gennemsnit for hele virksomhedens historie.,

Balance

Når vi dykker ned i den skattemæssige udvikling for Shin Nippon Biomedical Laboratories, Ltd., ser vi en gennemsnitlig aktivvækst. Det er interessant, at denne rate ligger på , hvilket afspejler både virksomhedens op- og nedture. Når man sammenligner kvartal for kvartal, justeres dette tal til . Et kig tilbage på det seneste år afslører en samlet aktivændring på NaN. Aktionærværdi, som vist ved den samlede egenkapital, er vurderet til NaN i rapporteringsvalutaen. Ændringen fra år til år i dette aspekt er NaN%.

common:word.in-mln

USD
Growth
TTM2022202120202019201820172016201520142013201220112010200920082007200620052004

balance-sheet.row.cash-and-short-term-investments

010533.169977286.5
5249.8
5141.5
5312.7
7447
4942.1
7276.3
9751.8
6787
6717.4
9129.3
10346.7
8926.8
6447.8
7180.7
7696
9000.5

balance-sheet.row.short-term-investments

0-423.6368.155.8
-233.7
-220.3
-1044.1
28.3
24.1
-70.1
27.7
-77.3
111.4
1042.2
710.1
404.4
353.3
160.3
1370.8
1295.2

balance-sheet.row.net-receivables

04760.43501.62954.1
2604.7
1986.8
2708.4
3134.2
3396.1
3449.3
3151.3
2918.7
2650.5
2538.8
2933.5
2737.8
2415.9
2393.7
1616.7
1330.5

balance-sheet.row.inventory

07329.44359.44071.4
4031.7
3600
6439.5
6965.6
7315.4
7592.9
5365.5
4451.7
6083.9
7481.5
7948.8
7824.1
8218.8
6682.1
5808.3
4438

balance-sheet.row.other-current-assets

01276.71276.5468.1
523.7
938.1
829.6
599.1
652.1
692
481.1
332.1
350.9
410.8
553.5
337.8
358.2
453
432.6
290.3

balance-sheet.row.total-current-assets

023899.616134.514780
12409.9
11666.4
15290.1
18145.9
16305.7
19010.5
18749.7
14489.5
15802.8
19560.4
21782.5
19826.5
17440.7
16709.5
15553.6
15059.3

balance-sheet.row.property-plant-equipment-net

018879.313155.812898
13699.7
13686.6
14654.2
17104.6
19893.6
19543.1
19205.1
17097.3
16718.6
17442.4
18409.3
18778.8
17967.2
16048.5
11847.7
8348.3

balance-sheet.row.goodwill

01438.80.30.8
0.4
0.5
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

0260.7212213
194
92
0
371.1
341.6
194.9
206.2
101.7
107.2
157.5
198.9
306.8
327.2
396.2
359.4
332.9

balance-sheet.row.goodwill-and-intangible-assets

01699.4212.3213.8
194.4
92.5
288.8
371.1
341.6
194.9
206.2
101.7
107.2
157.5
198.9
306.8
327.2
396.2
359.4
332.9

balance-sheet.row.long-term-investments

01240486458522
12242
27839
27113.8
19045.3
10417.8
1496.5
1273.6
928.7
545.2
-464.2
-301.8
-108.3
907
1075.7
-90.1
-946.8

balance-sheet.row.tax-assets

0325.81129.6521.6
1.8
11.4
11.4
15.7
1
63.2
71.2
92.2
239.7
513.8
610.7
323.3
442.7
200.6
173.1
137.7

balance-sheet.row.other-non-current-assets

034.235.437
454.5
1033
250
1570.3
1281
244
400.1
285.5
497
1438.1
1199.4
987.4
1018.1
822.4
1864.1
1553.6

balance-sheet.row.total-non-current-assets

033342.623178.222192.4
26592.4
42662.6
42318.3
38107.1
31934.9
21541.8
21156.1
18505.4
18107.6
19087.6
20116.5
20288
20662.1
18543.4
14154.3
9425.6

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

057242.239312.736972.4
39002.3
54329
57608.4
56253
48240.6
40552.4
39905.8
32994.9
33910.4
38648
41898.9
40114.5
38102.8
35252.8
29707.8
24484.9

balance-sheet.row.account-payables

0419.864.695
119.3
36.6
84.6
86.7
152.8
73
57.1
105.2
67.3
122.3
199.9
229.9
210.3
166.2
175.5
145.3

balance-sheet.row.short-term-debt

08923.22942.73486.8
5998.3
11348.2
11523.9
11607.7
10315.7
10679.5
8307.7
9238.2
6381.1
5929.9
5065.2
3494
2270.8
2492.5
1934.9
1930.2

balance-sheet.row.tax-payables

0603.7743.1683.2
502.3
69.3
182.1
175.9
1405
846.9
789.3
623.1
86.5
57.5
194.2
300.7
559.9
323.9
359.7
195.5

balance-sheet.row.long-term-debt-total

09837.56195.69199.2
8924.8
4603.2
7409
11298.4
12004.6
11517.2
13394
13481.5
15186.4
15884.8
16924.2
16365.5
11510.6
10174.7
6513.1
8002.2

Deferred Revenue Non Current

0-1064-68.2-642.4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

03009.82685.12317.4
2033.1
2092.7
2307.1
2045.4
2086
2496.2
2142.6
2295.4
1676.1
1720.7
1861
2667.2
2424.8
2791.9
2015
1518.9

balance-sheet.row.total-non-current-liabilities

09871.56215.69217.8
9669.3
8083.6
11389.8
14103.7
12269.8
11583
13459.6
13577
15709.4
16031.3
16932.5
16373.9
11523
10289.6
6641.6
8258.7

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

0357385.8529.3
707.5
708.5
484.7
492.3
602.5
378.1
448.3
405
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

030883.219589.521133.6
22620.4
25851.2
31392.7
33779.6
31765.9
30908.4
29390.7
30211.9
29845.3
30782.6
32099.1
30835.8
25144.5
22788.8
17895.3
17776

balance-sheet.row.preferred-stock

002620.8105.7
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

09679.19679.19679.1
9679.1
9679.1
9679.1
9679.1
9061.5
9061.5
9061.5
5391.1
5391.1
5391.1
5391.1
5391.1
5391.1
5391.1
5391.1
3352.7

balance-sheet.row.retained-earnings

013766.210196.33854.5
-2489
-10082.6
-12059
-8260.3
-7331.9
-7587.4
-6201.6
-5446.6
-4293.8
-886.6
1005.2
571.1
982.7
485.9
45.2
-144

balance-sheet.row.accumulated-other-comprehensive-income-loss

0460.2-2620.8-105.7
3901.4
18450.3
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-total-stockholders-equity

02306.4-314.32200.9
5196.6
10362.3
28538.6
21032.5
14717.4
8142.6
7573.1
2770.4
2909.2
3302.1
3331.4
3246.6
6498.3
6504.3
6380.8
3503.6

balance-sheet.row.total-stockholders-equity

026211.819561.115734.5
16288.1
28409
26158.7
22451.3
16447
9616.7
10433
2714.8
4006.5
7806.5
9727.7
9208.8
12872.1
12381.2
11817
6712.3

balance-sheet.row.total-liabilities-and-stockholders-equity

057242.239312.736972.4
39002.3
54329
57608.4
56253
48240.6
40552.4
39905.8
32994.9
33910.4
38648
41898.9
40114.5
38102.8
35252.8
29707.8
24484.9

balance-sheet.row.minority-interest

0147.2162104.3
93.8
68.8
57
22.1
27.8
27.2
82.2
68.2
58.7
58.9
72.1
70
86.2
82.8
-4.5
-3.3

balance-sheet.row.total-equity

02635919723.115838.8
16381.8
28477.8
26215.7
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

011980.47080.18286.9
12008.3
27618.7
26069.8
19073.7
10441.9
1426.4
1301.3
851.4
656.6
578
408.3
296.1
1260.2
1236
1280.6
348.5

balance-sheet.row.total-debt

018760.79138.312686.1
14923.1
15951.4
18932.8
22906.1
22320.4
22196.7
21701.7
22719.7
21567.6
21814.7
21989.4
19859.5
13781.4
12667.2
8448
9932.4

balance-sheet.row.net-debt

08227.62509.45455.3
9673.2
10809.9
13620.1
15487.4
17402.3
14920.4
11977.6
15932.7
14961.6
13727.6
12352.8
11337.1
7686.9
5646.8
2122.8
2227.2

Pengestrømsopgørelse

Det økonomiske landskab for Shin Nippon Biomedical Laboratories, Ltd. har set en bemærkelsesværdig ændring i det frie cash flow i løbet af den sidste periode, hvilket udviser et skift på NaN. Virksomheden udvidede for nylig sin aktiekapital ved at udstede NaN, hvilket markerer en forskel på NaN i forhold til det foregående år. Virksomhedens investeringsaktiviteter resulterede i et nettokasseforbrug på NaN i rapporteringsvalutaen. Dette er en forskydning på NaN fra året før. I samme periode har virksomheden registreret NaN, NaN og NaN, som er væsentlige for forståelsen af virksomhedens investerings- og afdragsstrategier. Virksomhedens finansieringsaktiviteter førte til et nettokasseforbrug på NaN, med en forskel fra år til år på NaN. Desuden afsatte virksomheden NaN til udbetaling af udbytte til sine aktionærer. Samtidig foretog virksomheden andre finansielle manøvrer, kaldet NaN, som også påvirkede pengestrømmen betydeligt i denne periode. Disse komponenter tegner tilsammen et omfattende billede af virksomhedens økonomiske status og strategiske tilgang til likviditetsstyring.

common:word.in-mln

USD
Growth
TTM2022202120202019201820172016201520142013201220112010200920082007200620052004

cash-flows.row.net-income

07759.68183.34175.6
3062.7
1650.7
-1508
-764.7
3550.3
-398.5
95.5
-511.2
-2861.9
-1138.9
411
199.6
856.1
975.9
575.1
-491.2

cash-flows.row.depreciation-and-amortization

01600.51177.41187.7
1229.2
1361.6
1472.8
1545.8
1592.1
1391.9
1318.4
1374.7
1592.9
1763.4
1938.4
1831.4
1819.5
1304.7
919.9
837

cash-flows.row.deferred-income-tax

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-236.4
0

cash-flows.row.stock-based-compensation

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
36.2
0

cash-flows.row.change-in-working-capital

0-2812.9723.3532
-907.3
1276.9
955.5
551.5
375.8
-1735.8
-847.8
-14.8
135.4
-421.1
-224.2
-422.8
106.5
-1648.2
-605.4
810.7

cash-flows.row.account-receivables

0-937-480-343
-619
-149
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.inventory

0-968.5-371.1-71.7
-445.3
-424.5
398.3
-70.7
-500.9
-1694.8
-559.8
1833.6
1218.2
-84.3
-73.5
-602.3
-1675.2
-793.9
-1055.6
327.3

cash-flows.row.account-payables

0-268.2-36.7-24.2
82.7
119.2
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-working-capital

0-639.21611.1970.8
74.3
1731.2
557.2
622.2
876.7
-40.9
-288
-1848.4
-1082.7
-336.8
-150.7
179.5
1781.6
-854.4
450.2
483.3

cash-flows.row.other-non-cash-items

0-2543.2-4131.3-1148.5
-366.2
-1396.5
423.9
-2182.5
-8858.1
-1413.7
-2186.2
-758.3
100.4
103.4
-381.7
-739.5
384.3
-183.6
65.6
-92.8

cash-flows.row.net-cash-provided-by-operating-activities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

0-4955.7-1614.3-1118
-1230.1
-1099.8
-1018.3
-1015.9
-1808.2
-1468.7
-1745.7
-810.8
-895.7
-957.9
-2158.5
-4070.8
-4671.5
-4927.5
-3968.9
-2029.6

cash-flows.row.acquisitions-net

0-1937.21200.81242.3
-4.6
1500.7
1815.5
91.5
3529.8
84.4
-186.3
0
49.2
-44.5
-42.8
-130.4
0
-106.6
0
-199.9

cash-flows.row.purchases-of-investments

0-1514.3-4194.1-895
-790.4
-9
-18.6
-1
-55.8
-208.4
-340.1
-109.1
-191.7
-204.8
-215.2
-1026.4
-158.2
-80
-995.1
-245.1

cash-flows.row.sales-maturities-of-investments

02532.2266.791.4
496.7
20.3
19.3
509
552.2
17.1
355.3
154
2
133
210.1
1947.2
0
116.4
0
27.3

cash-flows.row.other-investing-activites

0-55.572.3410.6
73.3
22.5
39.9
102.2
-932
482.8
144.3
15.7
29.1
224.7
34.4
477.8
14.4
950.7
184.5
2093.1

cash-flows.row.net-cash-used-for-investing-activites

0-5930.6-4268.5-268.7
-1455.1
434.8
837.8
-314.2
1286
-1092.8
-1772.6
-750.3
-1007.1
-849.5
-2172.1
-2802.6
-4815.3
-4047
-4779.6
-354.2

cash-flows.row.debt-repayment

0-5468.1-3492.3-4598.2
-4166.9
-4707.5
-5892.7
-6657.7
-6650.2
-6707.8
-7199.5
-5781.8
-4952
-4258.3
-3679.3
-2293.1
-2378
-2160.8
-1880.4
-1067.7

cash-flows.row.common-stock-issued

00.200
0
0
0
1227.8
0
7198.7
7218.6
16.9
0.2
517.4
0.2
8429.7
0
0
4040.6
0

cash-flows.row.common-stock-repurchased

0-0.200
0
0
-16.6
0
0
0
6043.7
6437.7
0
0
-190.6
-672.8
0
0
378.8
0

cash-flows.row.dividends-paid

0-2484.4-826.5-206.2
-123.6
0
0
0
0
0
-1.2
-1.2
-103.7
-98.5
-102.6
-203.3
-102.2
-102.1
-77.9
-93.2

cash-flows.row.other-financing-activites

014218.8-593.12333.4
2840.9
1205.9
1684.9
9245
6368
15.8
77.1
0
4676.4
3496.5
5805.2
-10.5
3489.5
6348.4
9.8
5924.1

cash-flows.row.net-cash-used-provided-by-financing-activities

06266.2-4912-2471.1
-1449.6
-3501.6
-4224.3
3815.1
-282.2
506.7
6138.7
671.6
-379.1
-343
1833
5250
1009.3
4085.5
2470.8
4763.2

cash-flows.row.effect-of-forex-changes-on-cash

0311.5496.729.6
-5.1
14.9
-87.5
-152.9
9.3
265.9
372.6
168.6
-79.8
-267.8
13.6
-594.3
-91.4
28.6
400.2
-115.2

cash-flows.row.net-change-in-cash

04648.9-27312036.6
108.5
-159.3
-2129.7
2498.2
-2326.8
-2476.2
2977.4
180.3
-2499.2
-1153.5
1418.1
2721.8
-731
515.7
-1153.6
5573.3

cash-flows.row.cash-at-end-of-period

09197.74548.87279.8
5243.3
5134.7
5294.1
7423.8
4925.6
7252.5
9728.7
6751.2
6570.9
9070.1
10223.6
8805.5
6083.7
6814.7
6299
7452.5

cash-flows.row.cash-at-beginning-of-period

04548.87279.85243.3
5134.7
5294.1
7423.8
4925.6
7252.5
9728.7
6751.2
6570.9
9070.1
10223.6
8805.5
6083.7
6814.7
6299
7452.5
1879.2

cash-flows.row.operating-cash-flow

040045952.84746.7
3018.3
2892.7
1344.3
-849.8
-3339.9
-2156
-1620.1
90.3
-1033.2
306.8
1743.6
868.7
3166.4
448.7
755.1
1063.6

cash-flows.row.capital-expenditure

0-4955.7-1614.3-1118
-1230.1
-1099.8
-1018.3
-1015.9
-1808.2
-1468.7
-1745.7
-810.8
-895.7
-957.9
-2158.5
-4070.8
-4671.5
-4927.5
-3968.9
-2029.6

cash-flows.row.free-cash-flow

0-951.74338.53628.7
1788.1
1792.9
326
-1865.7
-5148.1
-3624.8
-3365.8
-720.5
-1928.9
-651.1
-414.9
-3202.1
-1505.1
-4478.8
-3213.9
-966

Resultatopgørelse række

Shin Nippon Biomedical Laboratories, Ltd.s omsætning oplevede en ændring på NaN% sammenlignet med den foregående periode. Bruttofortjenesten for 2395.T rapporteres til at være NaN. Virksomhedens driftsomkostninger er NaN og viser en ændring på NaN% fra sidste år. Udgifterne til afskrivninger er NaN, hvilket er en ændring på NaN% fra sidste regnskabsperiode. Driftsudgifterne rapporteres at være NaN, hvilket viser en NaN% ændring fra år til år. Salgs- og marketingomkostninger er NaN, hvilket er en ændring på NaN% sammenlignet med året før. EBITDA baseret på de seneste tal er NaN, hvilket repræsenterer en NaN% vækst i forhold til året før. Driftsindtægterne er NaN, som viser en ændring på NaN% sammenlignet med året før. Ændringen i nettoindkomsten er NaN%. Nettoindkomsten for det sidste år var NaN.

common:word.in-mln

USD
Growth
TTM2022202120202019201820172016201520142013201220112010200920082007200620052004

income-statement-row.row.total-revenue

025090.917748.515110.5
14561.1
15658.7
16600.5
17244.5
14750.1
17835
16926.4
17154.1
15274
17371.9
19050.3
19540.2
19647.2
17289.4
13805.4
12295.7

income-statement-row.row.cost-of-revenue

012044.28061.27556.1
6945.4
9480.9
11396.4
12884.2
12059.1
11882.6
11178.2
12467.2
11978.1
12149.3
12825.3
12703.1
11958.4
10590.1
8417
8261.2

income-statement-row.row.gross-profit

013046.79687.37554.4
7615.7
6177.8
5204.1
4360.2
2691
5952.4
5748.2
4686.8
3295.8
5222.6
6225
6837.1
7688.8
6699.3
5388.4
4034.6

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

015.2191.1211.4
119.7
97.5
38.9
-69.8
168.5
162.4
170.5
195
486.2
389.8
542.1
229.5
176.1
30
-20.3
14.6

income-statement-row.row.operating-expenses

07801.45491.75024.9
5387.5
5348
5901.6
6152.7
6554.4
6588.7
6471.9
6114.9
5563.1
5301.5
5125.1
5523.2
5146.6
4832.2
4003.4
3759.1

income-statement-row.row.cost-and-expenses

019845.713552.912581
12332.8
14828.9
17298
19037
18613.5
18471.3
17650.2
18582.1
17541.2
17450.8
17950.4
18226.2
17105
15422.4
12420.4
12020.3

income-statement-row.row.interest-income

057.48.33
9.3
18.5
9.1
15.1
15.2
4
8.2
4.9
9.5
9.4
12.9
45.5
46.5
58.8
58.5
9.3

income-statement-row.row.interest-expense

0125.1126.6184.9
235
377.8
374
378.1
304.3
289.9
307.5
302.3
309.3
343.4
342.7
283.8
251.6
177.6
177.9
150

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

0251439861644
832
890
-810.5
1027.8
7413.8
237.8
819.3
916.8
-594.7
-1060.1
-688.9
-1114.4
-1686.1
-891.2
-809.9
-766.6

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

015.2191.1211.4
119.7
97.5
38.9
-69.8
168.5
162.4
170.5
195
486.2
389.8
542.1
229.5
176.1
30
-20.3
14.6

income-statement-row.row.total-operating-expenses

0251439861644
832
890
-810.5
1027.8
7413.8
237.8
819.3
916.8
-594.7
-1060.1
-688.9
-1114.4
-1686.1
-891.2
-809.9
-766.6

income-statement-row.row.interest-expense

0125.1126.6184.9
235
377.8
374
378.1
304.3
289.9
307.5
302.3
309.3
343.4
342.7
283.8
251.6
177.6
177.9
150

income-statement-row.row.depreciation-and-amortization

01600.51177.41187.7
1229.2
1361.6
1472.8
1545.8
1592.1
1391.9
1318.4
1374.7
1592.9
1763.4
1938.4
1831.4
1819.5
1304.7
919.9
837

income-statement-row.row.ebitda-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

05245.24195.62529.5
2228.3
829.8
-697.5
-1792.5
-3863.4
-636.3
-723.8
-1428.1
-3048.9
-843.7
343.8
463.9
1585.6
1125.8
772.2
-329

income-statement-row.row.income-before-tax

07759.68183.34175.6
3062.7
1650.7
-1508
-764.7
3550.3
-398.5
95.5
-511.2
-2861.9
-1138.9
411
199.6
856.1
975.9
575.1
-491.2

income-statement-row.row.income-tax-expense

01708.91016.2497.8
414.5
-308.1
2013.2
127.8
903.4
992.4
857.6
651.4
443.1
314.4
-116.6
412.7
264.1
433.6
309.4
-17

income-statement-row.row.net-income

06060.17127.63661.9
2550.4
1950.3
-3555.9
-915.9
2646.1
-1385.7
-755
-1152.9
-3304.1
-1442
534.5
-205.5
599.9
543.8
267.4
-472.4

Ofte stillede spørgsmål

Hvad er Shin Nippon Biomedical Laboratories, Ltd. (2395.T) samlede aktiver?

Shin Nippon Biomedical Laboratories, Ltd. (2395.T) samlede aktiver er 57242205000.000.

Hvad er virksomhedens årlige omsætning?

Den årlige omsætning er N/A.

Hvad er virksomhedens profitmargin?

Virksomhedens profitmargin er 0.522.

Hvad er virksomhedens frie pengestrøm?

Det frie cash flow er 85.787.

Hvad er virksomhedens nettoprofitmargin?

Nettofortjenstmargenen er 0.206.

Hvad er firmaets samlede omsætning?

Den samlede omsætning er 0.150.

Hvad er Shin Nippon Biomedical Laboratories, Ltd. (2395.T) nettoresultat (nettoindkomst)?

Nettoresultatet (nettoindkomsten) er 6060057000.000.

Hvad er virksomhedens samlede gæld?

Den samlede gæld er 18760662000.000.

Hvad er tallet for driftsudgifter?

Driftsudgifterne er 7801426000.000.

Hvad er firmaets likviditet?

Virksomhedens likviditet er 0.000.